GlaxoSmithKline Stock News

GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript)

British pharmaceutical giant GSK PLC on Tuesday announced a $1.4 billion deal to acquire Aiolos Bio Inc., boosting its respiratory portfolio.

GSK PLC (LSE:GSK, NYSE:GSK) should deliver better than expected fourth-quarter results on January 31, according to Barclays, amid heightened expectations driven by the robust performance of its RSV v

GSK on Tuesday said it had struck a deal to acquire asthma drug developer Aiolos Bio for up to $1.4 billion, as the British pharmaceutical giant pushes forward with plans to bolster its development pi

GSK PLC (LSE:GSK, NYSE:GSK) has moved to bolster its respiratory franching with the acquisition of Aiolos Bio for up to $1.4bn. It is paying an upfront $1 billion and $400 million based on certain re

GSK said it has bought Aiolos Bio for an upfront consideration of $1 billion, with the potential for an additional $400 million.

British drugmaker GSK on Tuesday said it would acquire clinical-stage biopharmaceutical firm Aiolos Bio for a $1 billion upfront payment and up to $400 million in certain success-based regulatory mile

The latest trading day saw GSK (GSK) settling at $39.64, representing a +1.1% change from its previous close.

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Wall Street's views on stocks and sectors can change tremendously in a short time. For example, in early 2022, the Street was sure that Luckin Coffee (OTC: LKNCY ) was dead and buried.

GSK PLC (LSE:GSK, NYSE:GSK) shares got a shot in the arm this morning after Jefferies took a more positive view of the pharmaceuticals giant. The US investment bank upgraded its rating to ‘buy' fr

GSK (GSK) concluded the recent trading session at $37.51, signifying a +1.21% move from its prior day's close.

AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth p

Pharmaceutical companies, GSK (GSK), Amneal Pharmaceuticals (AMRX) and Kaléo have agreed to delist some of their patents from the FDA's orange book. GSK withdrew four inhaler patents and Amneal withd